Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

NCT03862807 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis, Familial
Transthyretin Amyloidosis

Interventions

DRUG: Patisiran

Sponsor

Alnylam Pharmaceuticals